
Accelerate co-creation with external partners
Daiichi Sankyo Healthcare is taking on the challenge of creating new value that contributes to people's healthy and enriched lives by actively promoting co-creation with external partners, in line with its vision of "supporting quality of life in the 100-year life era. As an initiative based on the conclusion of this agreement, the two companies will begin joint development aimed at applying Kao's dermal formulation technology by leveraging the technology and knowledge accumulated through the development of our OTC drug products.
To date, Daiichi Sankyo Healthcare has pursued "scientific evidence," "customer satisfaction," and "continuous creation of new added value," and has worked to develop products with high functionality, efficacy, and safety by conducting exploratory research in-house as well as joint research with external research institutions and developing technologies with partner companies to which we outsource manufacturing. We have been striving to develop products with high functionality, efficacy, and safety.
The company intends to further accelerate its open innovation efforts to develop innovative healthcare products of higher quality by combining Daiichi Sankyo Healthcare's accumulated knowledge with a variety of external technologies.
About Daiichi Sankyo Healthcare
Daiichi Sankyo Healthcare is developing the OTC drug business, which consumers can select and purchase on their own, based on the Daiichi Sankyo Group* corporate philosophy of "providing pharmaceuticals that meet diverse medical needs.
Currently, we are expanding our business domain beyond OTC drugs to skin care and oral care, and are working to achieve our corporate slogan, "Fit for You: Your Partner in Creating a Healthy Lifestyle.
Through these businesses, we promote "self-care," the practice of taking care of one's own health, and contribute to the realization of a society in which everyone can continue to be healthy and beautiful.
*The Daiichi Sankyo Group is engaged in the business of innovative drugs (new drugs), generic drugs, vaccines, and over-the-counter (OTC) drugs.
| name of company | Daiichi Sankyo Healthcare Co. |
| Establishment | December 2005 |
| Location | 3-14-10 Nihonbashi, Chuo-ku, Tokyo |
| representative | Katsuhiko Yoshida |
| uniform resouce locator | https://www.daiichisankyo-hc.co.jp/ |
About Kao
Starting in 2021, Kao is promoting its mid-term management plan "K25" with the vision of "Protecting Future Lives: Sustainability as the only path".
We will continue to introduce ESG perspectives into our management, aiming to develop our business and provide better products and services to consumers and society, and to work toward our Purpose, "Realization of a prosperous, symbiotic world".
| name of company | Kao Corporation |
| Establishment | May 1940 |
| Location | 1-14-10 Kayabacho, Nihonbashi, Chuo-ku, Tokyo |
| representative | Yoshihiro Hasebe, Representative Director, President and Chief Executive Officer |
| uniform resouce locator | https://www.kao.com/jp/ |










